Health In Tech, Inc.
HIT Nasdaq Insurance Agents, Brokers & Service Financials FY2023–FY2025
Last close · Oct 23, 2026
$0.56
2.3%What Health In Tech, Inc. does
No business description yet.
- Legal name
- Health In Tech, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Accession · CIK
- 0001213900-26-034211
0002019505
Revenue and margins
Health In Tech, Inc. had $33.3M of revenue in fiscal 2025, up 71.0% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Health In Tech, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 7.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Health In Tech, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $2.4M | $7.8M | $7.7M |
| Current ratio | 1.4x | 5.1x | 3.1x |
| Quick ratio | 1.4x | 5.1x | 3.1x |
| Total assets | $11.5M | $15.8M | $23.1M |
| Total liabilities | $5.4M | $2.6M | $6.0M |
| Shareholders' equity | $6.1M | $13.2M | $17.1M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✕ | ✓ |
| Cash from operations exceeds net income | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | — | ✕ |
| Gross margin rose | — | ✕ | ✕ |
| Revenue rose relative to assets | — | ✕ | ✓ |
| F-score | — / 3 | 4 / 7 | 5 / 8 |
| Accruals ratio | 21.1% | −11.0% | −9.5% |
| Altman Z'' | — | — | — |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $19.2M | $19.5M | $33.3M |
| Provision for credit losses | — | $0.2M | $0.6M |
| Gross profit | $16.8M | $15.4M | $20.9M |
| Research and development | $2.0M | $2.8M | $1.6M |
| Interest expense | $0.0M | $0.5M | — |
| Pretax income | $3.4M | $0.9M | $1.7M |
| Income tax | $0.9M | $0.2M | $0.4M |
| Net income | $4.0M | $0.7M | $1.3M |
| Net income to common | $2.5M | $0.7M | — |
| Diluted EPS | — | $0.01 | $0.02 |
| Diluted shares | — | 0.05B | 0.06B |
| Cash flow | |||
| Cash from operations | $1.5M | $2.2M | $3.1M |
| Depreciation and amortization | $0.3M | $0.5M | $0.9M |
| Stock-based compensation | — | $0.5M | $1.6M |
| Balance sheet | |||
| Cash and short-term investments | $2.4M | $7.8M | $7.7M |
| Current assets | $6.9M | $10.8M | $16.2M |
| Current liabilities | $4.8M | $2.1M | $5.2M |
| Total assets | $11.5M | $15.8M | $23.1M |
| Total liabilities | $5.4M | $2.6M | $6.0M |
| Shareholders' equity | $6.1M | $13.2M | $17.1M |
| Margins | |||
| Gross margin | 88.0% | 79.2% | 62.8% |
| Net margin | 20.7% | 3.4% | 3.8% |
| Returns | |||
| Return on equity | 65.0% | 7.0% | 8.4% |
| Return on assets | 34.4% | 4.9% | 6.6% |
| Return on tangible equity | 40.6% | 5.1% | 7.5% |
| Growth | |||
| Revenue growth | — | 1.8% | 71.0% |
| Net income growth | — | −83.1% | 90.7% |
| EPS growth | — | — | 100.0% |
| Share count change | — | — | 7.6% |
| Financial health | |||
| Current ratio | 1.4x | 5.1x | 3.1x |
| Quick ratio | 1.4x | 5.1x | 3.1x |
| Capital allocation | |||
| Stock comp / revenue | — | 2.4% | 4.7% |
| Quality scores | |||
| Piotroski F-score | — | 4.0 | 5.0 |
| Accruals ratio | 21.1% | −11.0% | −9.5% |
Source: SEC EDGAR XBRL filings (CIK 0002019505). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.